Results 191 to 200 of about 32,048 (238)

Reticulated acanthoma with sebaceous differentiation: A case report. [PDF]

open access: yesMedicine (Baltimore)
Yu WT, Zhang Q, Shen H, Liu ZH.
europepmc   +1 more source

Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry. [PDF]

open access: yesEur Urol Open Sci
Monda SM   +16 more
europepmc   +1 more source

Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. [PDF]

open access: yesEClinicalMedicine
Bogdanski AM   +17 more
europepmc   +1 more source

Immune checkpoint inhibitors in children with replication-repair-deficient high-grade gliomas. The South London Paediatric & TYA Neuro-Oncology Network experience

open access: yes
Perez-Somarriba M   +25 more
europepmc   +1 more source

Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers [PDF]

open access: yesJournal of the National Cancer Institute, 2010
Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer ...
Laura Baglietto   +2 more
exaly   +6 more sources
Some of the next articles are maybe not open access.

Related searches:

Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6

Familial Cancer, 2017
Lynch Syndrome (LS) is the most common dominantly inherited colorectal cancer (CRC) predisposition and is caused by a heterozygous germline defect in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2. High microsatellite instability (MSI-H) and loss of MMR protein expression in tumours reflecting a defective MMR are indicators for LS,
Monika Morak   +9 more
openaire   +2 more sources

NordiQC Assessments of MSH6 Immunoassays

Applied Immunohistochemistry & Molecular Morphology, 2018
This paper is number 4 in a series developed through a partnership between ISIMM and Nordic immunohistochemical Quality Control for the purpose of reporting research assessing the performance characteristics of immunoassays in an external proficiency testing program.
Vyberg, Mogens   +3 more
openaire   +4 more sources

A novel infram deletion in MSH6 gene in glioma: Conversation on MSH6 mutations in brain tumors

Journal of Cellular Physiology, 2018
AbstractObjective and backgroundHistological and molecular information and biopsy help in the diagnosis of the type and grade of tumors and increase the value of estimation of the biological behavior of tumors. In this study, we focused on a consanguineous Iranian Family with high prevalence of brain tumors in their pedigree and reviewed the literature
Zeinab Deris Zayeri   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy